Ann V Schwartz1, Haiying Chen1, Walter T Ambrosius1, Ajay Sood1, Robert G Josse1, Denise E Bonds1, Adrian M Schnall1, Eric Vittinghoff1, Douglas C Bauer1, Mary Ann Banerji1, Robert M Cohen1, Bruce P Hamilton1, Tamara Isakova1, Deborah E Sellmeyer1, Debra L Simmons1, Amal Shibli-Rahhal1, Jeff D Williamson1, Karen L Margolis1. 1. University of California (A.V.S., E.V., D.C.B.), San Francisco, California 94143; Wake Forest School of Medicine (H.C., W.T.A., J.D.W.), Winston-Salem, North Carolina 27157; Louis Stokes VA Medical Center and Case Western Reserve University (A.S.), Cleveland, Ohio 44106; St. Michael's Hospital (R.G.J.), Toronto, ON M5B 1W8, Canada; National Heart Lung and Blood Institute (D.E.B.), National Institute of Health, Bethesda, Maryland 20892; Case Western Reserve University (A.M.S.), Cleveland, Ohio 44106; SUNY Downstate Medical Center and Kings County Hospital (M.A.B.), Brooklyn, New York 11203; University of Cincinnati College of Medicine (R.M.C.), Cincinnati, Ohio 45267; VA Medical Center and University of Maryland School of Medicine (B.P.H.), Baltimore, Maryland 21201; University of Miami (T.I.), Miami, Florida 33124; Division of Endocrinology (D.E.S.), Johns Hopkins School of Medicine, Baltimore, Maryland 21205; University of Utah and Salt Lake City Veterans Hospital (D.L.S.), Salt Lake City, Utah 84148; University of Iowa Carver College of Medicine (A.S.-R.), Iowa City, Iowa 52242; and Health Partners Institute for Education and Research (K.M.), Minneapolis, Minnesota 55425.
Abstract
CONTEXT: In trials, thiazolidinediones (TZDs) increase fracture risk in women, but the effects of discontinuation are unknown. OBJECTIVE: The objective was to investigate the effects of TZD use and discontinuation on fractures in women and men. DESIGN: This was a longitudinal observational cohort study using data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial bone ancillary study. Duration of TZD use and discontinuation during ACCORD, assessed every 2-4 months at clinic visits, were modeled as time-varying covariates in proportional hazards models for occurrence of first non-spine fracture. PARTICIPANTS: We studied a total of 6865 participants in ACCORD BONE. MAIN OUTCOME MEASURES: Main outcome measures were centrally adjudicated non-spine fracture. RESULTS:Average age was 62.4 (SD, 6.6) years; average duration of diabetes was 11.1 (SD, 7.8) years. Rosiglitazone was used by 74% and pioglitazone by 13% of participants. During a mean follow-up of 4.8 (SD, 1.5) years, 262 men and 287 women experienced at least one non-spine fracture. The fracture rate was higher in women with 1-2 years of TZD use (hazard ratio [HR] = 2.32; 95% confidence interval [CI], 1.49, 3.62) or >2 years of TZD use (HR = 2.01; 95% CI, 1.35, 2.98), compared with no use. The fracture rate was reduced in women who had discontinued TZD use for 1-2 years (HR = 0.57; 95% CI, 0.35, 0.92) or > 2 years (HR = 0.42; 95% CI, 0.24, 0.74) compared with current users. TZD use and discontinuation were not associated with non-spine fractures in men. CONCLUSIONS:TZD use was associated with increased non-spine fractures in women, but not men, with type 2 diabetes. When women discontinued TZD use, the fracture effects were attenuated.
RCT Entities:
CONTEXT: In trials, thiazolidinediones (TZDs) increase fracture risk in women, but the effects of discontinuation are unknown. OBJECTIVE: The objective was to investigate the effects of TZD use and discontinuation on fractures in women and men. DESIGN: This was a longitudinal observational cohort study using data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial bone ancillary study. Duration of TZD use and discontinuation during ACCORD, assessed every 2-4 months at clinic visits, were modeled as time-varying covariates in proportional hazards models for occurrence of first non-spine fracture. PARTICIPANTS: We studied a total of 6865 participants in ACCORD BONE. MAIN OUTCOME MEASURES: Main outcome measures were centrally adjudicated non-spine fracture. RESULTS: Average age was 62.4 (SD, 6.6) years; average duration of diabetes was 11.1 (SD, 7.8) years. Rosiglitazone was used by 74% and pioglitazone by 13% of participants. During a mean follow-up of 4.8 (SD, 1.5) years, 262 men and 287 women experienced at least one non-spine fracture. The fracture rate was higher in women with 1-2 years of TZD use (hazard ratio [HR] = 2.32; 95% confidence interval [CI], 1.49, 3.62) or >2 years of TZD use (HR = 2.01; 95% CI, 1.35, 2.98), compared with no use. The fracture rate was reduced in women who had discontinued TZD use for 1-2 years (HR = 0.57; 95% CI, 0.35, 0.92) or > 2 years (HR = 0.42; 95% CI, 0.24, 0.74) compared with current users. TZD use and discontinuation were not associated with non-spine fractures in men. CONCLUSIONS:TZD use was associated with increased non-spine fractures in women, but not men, with type 2 diabetes. When women discontinued TZD use, the fracture effects were attenuated.
Authors: Henry G Bone; Robert Lindsay; Michael R McClung; Alfonso T Perez; Marsha G Raanan; Robert G Spanheimer Journal: J Clin Endocrinol Metab Date: 2013-09-20 Impact factor: 5.958
Authors: J L C Borges; J P Bilezikian; A R Jones-Leone; A P Acusta; P D Ambery; A J Nino; M Grosse; L A Fitzpatrick; A R Cobitz Journal: Diabetes Obes Metab Date: 2011-11 Impact factor: 6.577
Authors: D Seto-Young; D Avtanski; G Parikh; P Suwandhi; M Strizhevsky; T Araki; Z Rosenwaks; L Poretsky Journal: Horm Metab Res Date: 2011-02-14 Impact factor: 2.936
Authors: John P Bilezikian; Robert G Josse; Richard Eastell; E Michael Lewiecki; Colin G Miller; Margaret Wooddell; Allison R Northcutt; Barbara G Kravitz; Gitanjali Paul; Alexander R Cobitz; Antonio J Nino; Lorraine A Fitzpatrick Journal: J Clin Endocrinol Metab Date: 2013-02-28 Impact factor: 5.958
Authors: Sanjay Kumar; Sandra J Hoffman; Rana Samadfam; Peter Mansell; Jacquelin Jolette; Susan Y Smith; Robert E Guldberg; Lorraine A Fitzpatrick Journal: J Bone Miner Res Date: 2013-07 Impact factor: 6.741
Authors: Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray Journal: Lancet Date: 2009-06-06 Impact factor: 79.321
Authors: Ann V Schwartz; Karen L Margolis; Deborah E Sellmeyer; Eric Vittinghoff; Walter T Ambrosius; Denise E Bonds; Robert G Josse; Adrian M Schnall; Debra L Simmons; Trisha F Hue; Lisa Palermo; Bruce P Hamilton; Jennifer B Green; Hal H Atkinson; Patrick J O'Connor; Rex W Force; Douglas C Bauer Journal: Diabetes Care Date: 2012-07 Impact factor: 19.112
Authors: Harald Sourij; Roland Edlinger; Friedrich Prischl; Martin Auinger; Alexandra Kautzky-Willer; Marcus D Säemann; Rudolf Prager; Martin Clodi; Guntram Schernthaner; Gert Mayer; Rainer Oberbauer; Alexander R Rosenkranz Journal: Wien Klin Wochenschr Date: 2016-04 Impact factor: 1.704